Abstract:Transcatheter aortic valve replacement (TAVR) is currently the first-line treatment for the patients with moderate to severe aortic stenosis. The high incidence of perioperative atrial fibrillation (POAF) in TAVR is significantly associated with worse prognosis. However, the mechanism of new-onset AF after TAVR is not clear, and the prevention, treatment and prognosis of POAF are still in the exploratory stage. This article reviews the research progress in the incidence, potential mechanisms, predictive factors, adverse outcomes, prevention and treatment of POAF after TAVR.